Abstract: The invention proposes an agent for the treatment of tumor diseases, for example the multiple myeloma, said agent acting upon NK cells through the activation of an anti-tumor immune response after stimulation of the NKp30 receptor and the natural cytotoxicity receptors (NCR). Said agent contains in an acceptable carrier material a physiologically effective amount of the BAT3 protein and/or BAT3/antiCD138 or BAT3-specific antibodies or derivatives of these substances. According to the principle identical to that adopted for the BAT3/anti-CD138 protein the invention may also be used for the treatment of CD138-negative tumors. For this purpose the antiCD138 component with an antibody fragment is replaced by an optional tumor antigen and the respective agent is used for the therapy of tumors expressing this tumor antigen.

Abstract: Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and proteasome inhibitors in combination are disclosed.

Abstract: The invention relates to a preparation for the treatment of pigmentation disorders. The preparation contains a physiologically active quantity of the DCoH protein, the DNA and/or RNA coding for the protein or DCoH antibodies or antiserum as active ingredient in a pharmaceutically suitable excipient. The invention also relates to the use of DCoH, the DNA and/or RNA coding for same or DCoH antibodies or antiserum as active ingredient in the production of such a preparation.

Abstract: The invention relates to a means for diagnosing tumours, especially malignant tumours in the human body and the animal body, using at least one substance which interacts with DCoH for in vitro diagnosis.